The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: A prospective single-center study

Urologic Oncology: Seminars and Original Investigations

Volumn 30, Issue 5, 2012, Pages 704-710

  Baldazzi, Valentina ^a   Tassi, Renato ^a   Lapini, Alberto ^a   Santomaggio, Carmine ^a   Carini, Marco ^a   Mazzanti, Roberto ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Hypothyroidism; Renal cell carcinoma; Sunitinib

Indexed keywords

LEVOTHYROXINE; LIOTHYRONINE; SUNITINIB; THYROTROPIN; THYROXINE;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; COHORT ANALYSIS; FEMALE; HUMAN; HYPOTHYROIDISM; KIDNEY METASTASIS; LIOTHYRONINE BLOOD LEVEL; MALE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; THYROID FUNCTION TEST; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TREATMENT DURATION;

AGED; ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYPOTHYROIDISM; INDOLES; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSPECTIVE STUDIES; PYRROLES; THYROID FUNCTION TESTS; THYROTROPIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84866746182     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2010.07.015     Document Type: Article

References (27)

1. Sutent (sunitinib malate) [pakage insert] 2006, Pfizer Inc., New York (NY), revised Aug 2008.
2. Motzer R.J., Hutson T.E., Tomczak P., et al. Overall survival and updated results for Sunitinib compared with interferon-α in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:3584-3590.
3. Rini B.I., Tamaskar I., Shaheen P., et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with Sunitinib. J Natl Cancer Inst 2007, 99:81-83.
4. Wolter P., Dumez H., Schöffski P. Sunitinib and hypothyroidism. N Engl J Med 2007, 356:1580. Author reply 1580-1.
5. Desai J., Yassa L., Marqusee E., et al. Hypothyroidism after Sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 2006, 145:660-664.
6. Wong E., Rosen L.S., Mulay M., et al. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 2007, 17:351-355.
7. Martorella AJ, Omry G, Hann LE, et al. Receptor kinase (RPT) inhibitor SU11248 may cause hypothyroidism in a selected group of patients with metastatic renal cell carcinoma. Proceedings of the 88th Annual Meeting of the Endocrine Society. Boston, (MA), June 2006.
8. Mannavola D., Coco P., Vannucchi G., et al. A novel tyrosine-kinase selective inhibitor, Sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 2007, 92:3531-3534.
9. Shaheen P.E., Tamskar I.R., Salas R., et al. Thyroid function tests abnormalities in patients with metastatic renal cell carcinoma treated with Sunitinib. J Clin Oncol 2006, 24(18S):4065.
10. Wolter P., Stefan C., Decallonne B., et al. The clinical implications of Sunitinib-induced hypothyroidism: A prospective evaluation. Br J Cancer 2008, 99:448-454.
11. Rini B.I., Tamaskar I., Shaheen P., et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with Sunitinib. J Natl Cancer Inst 2007, 99:81-83.
12. Garfield D., Herkbergs A., Davis P.J. RE: Hypothyroidism in patients with metastatic renal cell carcinoma treated with Sunitinib. J Nat Canc Inst 2007, 99:974-977.
13. Cristofanilli M., Yamamura Y., Kau S.W. Thyroid Hormone and breast carcinoma. Primary Hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer 2005, 103:1122-1128.
14. Hercbergs A.A., Goyal L.K., Suh J.H., et al. Propylthiouracil-induced chemical hypothyroidism with high dose tamoxifen prolongs survival in recurrent high grade glioma: A phase I/II study. Anticancer Res 2003, 23:617-626.
15. Nelson M., Hercbergs A., Rybicki L., et al. Association between development of hypothyroidism and improved survival in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 2006, 132:1041-1046.
16. Davis P.J., Davis F.B., Lin H.-Y., et al. Cell surface receptor for thyroid hormone and tumor cell proliferation. Expert Rev Endocrinol Metab 2007, 1:753-761.
17. Baskin H.J., Cobin R.H., Duick D.S., et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract 2002, 8:457-469. American Association of Clinical Endocrinologists.
18. Surks M.I., Ortiz E., Daniels G.H., et al. Subclinical thyroid disease: Scientific review and guidelines for diagnosis and management. JAMA 2004, 29:228-238.
19. Muto A., Baldazzi V., Lapini A., et al. Sunitinib induced hypothyroidism in a patient on levothyroxine. Ann Oncol 2009, 20:87. 11th National Congress of Medical Oncology October 10-13, 2009: Milan, Italy.
20. Wolter P, Stefan C, Decallonne B, et al. Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of Sunitinib in patients with advanced renal cell cancer. Proceedings of the ASCO Meeting. Chicago, (IL) May, 2008. [Abstract 5126].
21. Prummel M.F., Laurberg P. Interferon-α and autoimmune thyroid disease. Thyroid 2003, 13:547-551.
22. de Groot J.W., Zonnenberg B.A., Plukker J.T., et al. Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin Pharmacol Ther 2005, 78:433-438.
23. de Groot J.W., Links T.P., van der Graaf W.T. Tyrosine kinase inhibitors causing hypothyroidism in a patient on levothyroxine. Ann Oncol 2006, 17:1719-1720.
24. Curran P.G., DeGroot L.J. The effect of hepatic enzyme-inducing drugs on thyroid hormones and the thyroid gland. Endocr Rev 1991, 12:135-150.
25. Houk B.E., Bello C.L., Kang D., et al. A population pharmacokinetic meta-analysis of Sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res 2009, 15:2497-2506.
26. Houk B.E., Bello C.L., Poland B., et al. Relationship between exposure to Sunitinib and efficacy and tolerability endpoints in patients with cancers: Results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 2010, 66(2):357-371.
27. Garfield H.D., Wolter P., Hercbergs A., et al. Documentation of thyroid function in clinical studies with Sunitinib: Why does it matter?. J Clin Oncol 2008, 26:5131-5132.